10 telemedicine trials as of 2/22/21

14 alpha synuclein trials as of 2/22/21

10 gene therapy trials as of 2/22/21

PHASE Not Applicable

60+ trials per "Review of disease modifying therapies" document*



... and click on country/state to view trial listings.



Note: 609 total active trials includes 355 recruiting, 126 not yet recruiting, 31 enrolling by invitation and 97 no longer recruiting.

An INTERVENTIONAL STUDY (or Clinical Trial) is a clinical study in which participants are assigned an intervention such as a medication, device, or procedure, so that researchers can evaluate its effects on biomedical or health-related outcomes.  Participants may receive diagnostic, therapeutic, or other types of interventions.  See trial phase descriptions at bottom of page. 

(source: https://clinicaltrials.gov/ct2/about-studies/glossary#I)

609 active PD interventional studies worldwide are registered on ClinicalTrials.gov, as of February 22, 2021. 

Active studies include trials that are recruiting, not yet recruiting, enrolling by invitation or no longer recruiting.

TRIAL PHASE Definitions
source:  https://clinicaltrials.gov/ct2/about-studies/glossary#P

Food and Drug Administration (FDA) categories for describing the clinical trial of a drug based on the study's characteristics, such as the objective and number of participants.
Early Phase 1: Exploratory study involving very limited human exposure to the drug, with no therapeutic or diagnostic goals (for example, screening studies, microdose studies)
Phase 1: Studies that are usually conducted with healthy volunteers and that emphasize safety. The goal is to find out what the drug's most frequent and serious adverse events are and, often, how the drug is metabolized and excreted.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition). For example, participants receiving the drug may be compared with similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing. These including postmarket requirement and commitment studies that are required of or agreed to by the sponsor. These studies gather additional information about a drug's safety, efficacy, or optimal use.

Phase Not Applicable: Describes trials without FDA-defined phases, including trials of devices or behavioral interventions.

​​Reporting requirements for clinical trials registered on ClinicalTrials.gov

2007: Congress Passes Law (FDAAA) Expanding ClinicalTrials.gov Submission Requirements
2008: ClinicalTrials.gov Releases Results Database

​2016: Final Rule for Clinical Trials Registration and Results Information Submission (Final Rule for FDAAA 801)

Reported Results for Completed PD Trials with Primary Completion Date after 1/1/17

85 exercise-related trials as of 2/22/21

5 cognitive therapy trials as of 2/22/21

8 dyskinesia trials as of 2/22/21


80 DBS-related trials as of 2/22/21

^ includes trials of devices or behavioral interventions.

Parkinson's Disease interventional studies



buttons link to ClinicalTrials.gov.


To view publications of completed studies, you can search PubMed to find publication abstracts and authors, as well as links to full publications. Helpful keywords to use in a search are trial name, trial NCT# (i.e., ClinicalTrials.gov trial ID), principal investigator name, and sponsor name.  PubMed is a free resource developed by the National Center for Biotechnology Information (NCBI) at the U.S. NIH.    

Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.